Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 7
2016 8
2017 12
2018 12
2019 16
2020 21
2021 27
2022 20
2023 42
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: in the last 5 years. Clear all
Page 1
Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer.
Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, Li CS, Qian Y, Xu PP, Leng XX, Wang LW, Tu SP, Zhong M, Zhao G, Chen JX, Wang Z, Liu Q, Hong J, Chen HY, Chen YX, Fang JY. Jiang SS, et al. Cell Host Microbe. 2023 May 10;31(5):781-797.e9. doi: 10.1016/j.chom.2023.04.010. Epub 2023 May 1. Cell Host Microbe. 2023. PMID: 37130518 Free article.
Immune checkpoint blockade therapy with anti-PD-1 monoclonal antibody (mAb) is a treatment for colorectal cancer (CRC). ...We found that patients with metastatic CRC who fail to respond to immunotherapy had a greater abundance of Fusobacterium nucle …
Immune checkpoint blockade therapy with anti-PD-1 monoclonal antibody (mAb) is a treatment for colorectal cancer (CRC). …
Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer.
Wang N, Fang JY. Wang N, et al. Trends Microbiol. 2023 Feb;31(2):159-172. doi: 10.1016/j.tim.2022.08.010. Epub 2022 Sep 1. Trends Microbiol. 2023. PMID: 36058786 Review.
Colorectal cancer (CRC), one of the most prevalent cancers, has complex etiology. The dysbiosis of intestinal bacteria has been highlighted as an important contributor to CRC. Fusobacterium nucleatum, an oral anaerobic opportunistic pathogen, is enrich …
Colorectal cancer (CRC), one of the most prevalent cancers, has complex etiology. The dysbiosis of intestinal bacteria has bee …
A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche.
Zepeda-Rivera M, Minot SS, Bouzek H, Wu H, Blanco-Míguez A, Manghi P, Jones DS, LaCourse KD, Wu Y, McMahon EF, Park SN, Lim YK, Kempchinsky AG, Willis AD, Cotton SL, Yost SC, Sicinska E, Kook JK, Dewhirst FE, Segata N, Bullman S, Johnston CD. Zepeda-Rivera M, et al. Nature. 2024 Apr;628(8007):424-432. doi: 10.1038/s41586-024-07182-w. Epub 2024 Mar 20. Nature. 2024. PMID: 38509359 Free PMC article.
Fusobacterium nucleatum (Fn), a bacterium present in the human oral cavity and rarely found in the lower gastrointestinal tract of healthy individuals(1), is enriched in human colorectal cancer (CRC) tumours(2-5). ...Here, to delineate Fn genetic facto …
Fusobacterium nucleatum (Fn), a bacterium present in the human oral cavity and rarely found in the lower gastrointestinal trac …
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
Gao Y, Bi D, Xie R, Li M, Guo J, Liu H, Guo X, Fang J, Ding T, Zhu H, Cao Y, Xing M, Zheng J, Xu Q, Xu Q, Wei Q, Qin H. Gao Y, et al. Signal Transduct Target Ther. 2021 Nov 19;6(1):398. doi: 10.1038/s41392-021-00795-x. Signal Transduct Target Ther. 2021. PMID: 34795206 Free PMC article.
Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of …
Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are o …
Fusobacterium nucleatum and Colorectal Cancer.
Li R, Shen J, Xu Y. Li R, et al. Infect Drug Resist. 2022 Mar 17;15:1115-1120. doi: 10.2147/IDR.S357922. eCollection 2022. Infect Drug Resist. 2022. PMID: 35321079 Free PMC article. Review.
Fusobacterium nucleatum (F.n) is an oral anaerobic gram-negative bacillus that can colonize into the colon tissues through bloodstream infection. F.n have been found to be involved in both the occurrence and metastasis of colorectal cancer (CRC) throug …
Fusobacterium nucleatum (F.n) is an oral anaerobic gram-negative bacillus that can colonize into the colon tissues through blo …
Fusobacterium nucleatum and oral cancer: a critical review.
McIlvanna E, Linden GJ, Craig SG, Lundy FT, James JA. McIlvanna E, et al. BMC Cancer. 2021 Nov 13;21(1):1212. doi: 10.1186/s12885-021-08903-4. BMC Cancer. 2021. PMID: 34774023 Free PMC article. Review.
Notable examples include Helicobacter pylori-mediated inflammation in gastric cancer and more recently Fusobacterium nucleatum-mediated inflammation in colorectal cancer. Fusobacterium nucleatum is a Gram-negative anaerobic bacteri …
Notable examples include Helicobacter pylori-mediated inflammation in gastric cancer and more recently Fusobacterium nuclea …
Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.
Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, Yajuk O, Isaacson B, Abed J, Maalouf N, Nissan A, Sandbank J, Yehuda-Shnaidman E, Ponath F, Vogel J, Mandelboim O, Granot Z, Straussman R, Bachrach G. Parhi L, et al. Nat Commun. 2020 Jun 26;11(1):3259. doi: 10.1038/s41467-020-16967-2. Nat Commun. 2020. PMID: 32591509 Free PMC article.
Fusobacterium nucleatum is an oral anaerobe recently found to be prevalent in human colorectal cancer (CRC) where it is associated with poor treatment outcome. ...Thus, targeting F. nucleatum or Fap2 might be beneficial during treatment of breas …
Fusobacterium nucleatum is an oral anaerobe recently found to be prevalent in human colorectal cancer (CRC) wher …
Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.
Ou S, Wang H, Tao Y, Luo K, Ye J, Ran S, Guan Z, Wang Y, Hu H, Huang R. Ou S, et al. Front Cell Infect Microbiol. 2022 Nov 29;12:1020583. doi: 10.3389/fcimb.2022.1020583. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36523635 Free PMC article. Review.
Colorectal cancer(CRC) is the third most frequent malignant tumor. The gut microbiome acts as a vital component of CRC etiology. Fusobacterium nucleatum(Fn) is a key member of colorectal cancer-associated bacteria. But we lack a systemati …
Colorectal cancer(CRC) is the third most frequent malignant tumor. The gut microbiome acts as a vital component of CRC etiolog …
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications.
Wong SH, Yu J. Wong SH, et al. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704. doi: 10.1038/s41575-019-0209-8. Epub 2019 Sep 25. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31554963 Review.
Colorectal cancer (CRC) accounts for about 10% of all new cancer cases globally. Located at close proximity to the colorectal epithelium, the gut microbiota comprises a large population of microorganisms that interact with host cells to regulate many p …
Colorectal cancer (CRC) accounts for about 10% of all new cancer cases globally. Located at close proximity to the c …
Antibacterial Fusobacterium nucleatum-Mimicking Nanomedicine to Selectively Eliminate Tumor-Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer.
Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, Zhu J, Zhang L, Wang Y, Fang H, Zhou J, Li M, Yang Y, Liu Z, Chen Q. Chen L, et al. Adv Mater. 2023 Nov;35(45):e2306281. doi: 10.1002/adma.202306281. Epub 2023 Oct 2. Adv Mater. 2023. PMID: 37722134
As a result, the therapeutic responses of F. nucleatum-colonized tumors to ICB therapies can be successfully restored, as demonstrated in an F. nucleatum-infected subcutaneous CT-26 tumor model, chemically induced spontaneous colorectal cancer models, …
As a result, the therapeutic responses of F. nucleatum-colonized tumors to ICB therapies can be successfully restored, as demonstrate …
129 results